Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novartis AG Common Stock (NY:NVS)

109.59 +1.13 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
45 46 Next >
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pharmacovigilance (PV) Outsourcing Market Size, Share, Trends, Industry Analysis, Growth and Forecast 2022-2028
Pharmacovigilance (PV) Outsourcing Market 2022-2028, Segmentation, Swot Analysis including Key Players like – Accenture, C3i Solutions, Clintec, Covance, ELC Group, Ergomed, IQVIA, Novartis, Parexel 
Via SBWire
This Company Is Making Progress In Its Fight Against Rare, Terminal Cancers
Photo by National Cancer Institute on Unsplash 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Suspends Some Investment, Business Activities In Russia
Via Benzinga
Morning Brief: Top Stories Dominating Financial Media on Tuesday, March 22
CNBC 
Via Benzinga
Lucky Day
Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund. 
Via Talk Markets
Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study
Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal... 
Via Benzinga
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Why Another ADHD Stimulant? Cingulate Inc. Believes It's All About The Timing
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. People diagnosed with attention... 
Via Benzinga
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
Via Benzinga
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE: NVS) Kisqali (ribociclib) plus letrozole... 
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene... 
Via Benzinga
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Renewable Energy Investment Market Size, Share, Trends, Industry Growth, and Forecast 2028 Top Key Players Spectrum, Roche, Pfizer, Novartis, Merck, Bayer, Healthcare Amgen
Renewable Energy Investment Market Size, Share, Growth, Industry Trends, Business Scope, Global Providers, COVID-19 Impact and Forecast 2028 
Via SBWire
Exposures COVID-19
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing... 
Via Benzinga
Friday the 13th on the 18th
Today stock markets more or less panicked over the fear of war. 
Via Talk Markets
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Novartis Highlights Focus on Creating Value for Stakeholders and Society in New Integrated Report
SOURCE: 3BL Alerts 
Via 3BL Media
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19
Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have  
Via Benzinga
Global Diversification: Switzerland And The Philippines
One way to avoid or defend against slowing growth in the US is to own positions in other countries. There is likely a fund for almost any developed country you can think of that owns a basket of stocks... 
Via Talk Markets
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.